$226M in cash, cash equivalents, restricted cash and short-term investments as of June 30, 2025, expected to fund operations for over two years before accounting for anticipated ZEVASKYN revenue beginning in 3Q 2025 and projected profitability in 1H 2026
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces employee inducement grants
- AscellaHealth highlights value of HUB partnership with Abeona Therapeutics
- Abeona Therapeutics Amends Loan Agreement with Avenue
- Abeona Therapeutics’ Gene Therapy Trial for MPS IIIA: A Promising Update
- Abeona announces ZEVASKYN available at new Qualified Treatment Center